Kobo Biotech Ltd Stock Price Today (NSE: KOBO)

Kobo Biotech Ltd

4.33+0.20 (+4.84%)
Market Closed

Fundamental Score

...

Kobo Biotech Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Kobo Biotech Ltd share price today is 4.33, up +4.84% on NSE/BSE as of 19 June 2026. Kobo Biotech Ltd (KOBO) is a Small-cap company in the Commodity Chemicals sector with a market capitalisation of 6.39 (Cr). The 52-week high for KOBO share price is 4.33 and the 52-week low is 1.99.

Kobo Biotech Ltd Share Price Chart — NSE/BSE Historical Performance

No data
High
4.33
Low
2.58
Volume
12.1K
Change
+31.93%

Kobo Biotech Ltd share price chart: 31.93% return over the past month. 52-week high ₹4.33, 52-week low ₹1.99.

Kobo Biotech Ltd — Last 10 Trading Days

DateOpenHighLowCloseVolume
4.334.334.334.3324.53K (Cr)
4.134.134.134.1339.53K (Cr)
3.943.943.943.9423.60K (Cr)
3.763.763.763.7613.79K (Cr)
3.593.593.593.597.19K (Cr)
3.423.423.423.4210.61K (Cr)
3.263.263.263.267.19K (Cr)
3.113.113.113.1113.87K (Cr)
2.972.972.972.9715.70K (Cr)
2.832.832.832.837.08K (Cr)

Kobo Biotech Ltd — Last 12 Months Price History

MonthOpenHighLowCloseChange
4.134.334.134.33+4.84%
2.713.942.583.94+45.39%
2.273.012.242.85+25.55%
2.502.622.172.23-10.80%
2.883.192.502.51-12.85%
2.502.642.062.62+4.80%
2.762.761.992.39-13.41%
3.273.272.822.82-13.76%
2.393.582.203.44+43.93%
2.252.462.082.40+6.67%
2.432.652.202.35-3.29%
2.542.902.312.43-4.33%

AI Research Briefing

Powered by Gemini · 2026-04-10

This microcap commodity chemical company in CIRP is a value trap with significant downside risk.

Research Confidence
4.0/10Low
DEBT TRAP TURNAROUNDBreakdown. 1M: -22.09%.Expensive. Negative P/E ratio compared to an industry P/E of 20.98x.

WHAT'S HAPPENING NOW (last 2-4 weeks)

No major catalysts found after live search. Kobo Biotech's share price was The stock's 52-week range is to The company is undergoing Corporate Insolvency Resolution Process (CIRP).

CORE STORY (THE REAL GAME)

This is not a turnaround story; it's a potential value trap in a commodity chemical microcap. Market likely pricing in a distressed asset play with hopes of restructuring or acquisition.

Why Now
  • Micro-cap speculation
  • CIRP hopes
Potential Catalysts
  • Successful debt restructuring
  • Acquisition by a larger player
  • Negative news on CIRP
Key Risks
  • Micro/SME cap - illiquidity risk
  • Ongoing Corporate Insolvency Resolution Process (CIRP)
  • Negative ROCE of -52.9%
Institutional Activity

No FII/DII interest. Promoter holding steady at 44.95%.

Macro Context

Indian chemical production projected to increase by 10.9% in 2026, but Kobo's financials are a major headwind.

Cash Flow Quality

Free Cash Flow 5Y: ₹124.71 Cr, but recent profitability is weak.

3–6 Month Outlook

CIRP outcome will determine the future. Without successful restructuring, the company faces liquidation.

Primary Thesis Risk

Failure of CIRP leading to liquidation.

For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.

Returns & Performance

Return on Equity (ROE)

N/A

Profit generated per ₹1 of shareholder equity

Poor

Return on Capital (ROCE)

-52.90%

Returns generated on total capital deployed

Oper. Profit Margin (5Y Avg)

N/A

Average operating profit margin over 5 years

Dividend Yield

0.00%

Annual dividend as % of current share price

Kobo Biotech Ltd Valuation Check

Price to Earnings (P/E)

N/A

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

20.98x

Average P/E of all peers in this sector

Market-cap Classification
Small-cap
Higher growth potential with higher volatility.

Shareholding Pattern

Excellent

Promoter Holding

44.95%

% shares held by company founders/management

FII Holding

N/A

% shares held by foreign institutional investors

DII Holding

N/A

% held by domestic mutual funds, LIC, banks

Excellent

Promoter Pledged %

0.00%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Poor

Profit Growth (Quarterly YoY)

-8.13%

Net profit growth vs same quarter last year

Revenue Growth (Quarterly YoY)

N/A

Revenue growth vs same quarter last year

Revenue Growth (5-Year CAGR)

N/A

Compounded annual revenue growth over 5 years

Good

EPS Growth (5-Year CAGR)

12.21%

Earnings per share growth over 5 years

Good

Net Profit Growth (5-Year CAGR)

12.21%

Compounded annual net profit growth over 5 years

Balance Sheet Health

Debt to Equity Ratio

N/A

Total debt ÷ equity. Below 0.5 = financially healthy

Interest Coverage Ratio

N/A

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

124.71 (Cr)

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Kobo Biotech Ltd Fundamental Analysis & Valuation Benchmarking

Educational evaluation of KOBO across key market metrics for learning purposes.

Positive Indicators

2 factors identified

Strong Cash Generation (₹124.71 Cr over 5Y)

Observation: Healthy free cash flow generation supports growth and returns.

Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

2 factors identified

Suboptimal ROCE (-52.90%)

Observation: Returns on capital employed are below expectations.

Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.

No Dividend Distribution

Observation: Company does not currently pay dividends to shareholders.

Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.

Kobo Biotech Ltd vs Commodity Chemicals Peers

Peer Comparison - Commodity Chemicals

Compare Kobo Biotech Ltd with 10 other companies in the same sector

11 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
20.3/100
4
₹6.39
-52.90%
Poor
12.21%
Good
0.00%
SRF Ltd...
SRF503806
49.8/100
2737
₹86606.52
53.5
Average
10.37%
Average
12.27%
Average
0.3
Excellent
4.40%
Average
15.30%
Excellent
0.25%
14.9/100
775
₹20261.08
62.2
Average
1.20%
Poor
3.96%
Poor
0.3
Excellent
-47.92%
Poor
7.53%
Good
1.38%
57/100
1448
₹17120.52
17.4
Average
15.56%
Good
15.67%
Good
0.7
Good
94.55%
Excellent
17.00%
Excellent
0.74%
52.8/100
516
₹7381.56
11.6
Average
7.08%
Poor
9.57%
Poor
0.0
Excellent
3.30%
Average
8.86%
Good
3.58%
Ghcl Ltd...
GHCL500171
40.4/100
463
₹5520.31
9.7
Average
18.57%
Good
24.19%
Excellent
0.0
Excellent
8.63%
Good
-0.75%
Poor
2.09%
19.7/100
18
₹5397.73
9306.4
Average
2.12%
Poor
2.57%
Poor
0.0
Excellent
173.71%
Excellent
0.00%
24.4/100
222
₹4503.74
-5.93%
Poor
1.83%
Poor
1.0
Good
28.15%
Excellent
0.00%
68.7/100
1972
₹4106.65
43.7
Average
32.05%
Excellent
41.76%
Excellent
0.1
Excellent
38.64%
Excellent
27.58%
Excellent
0.22%
28/100
687
₹3866.17
25774.5
Average
-1.13%
Poor
-0.34%
Poor
0.1
Excellent
8.37%
Good
3.01%
59.7/100
72
₹3614.14
23.9
Average
17.58%
Good
23.34%
Excellent
0.0
Excellent
17.17%
Excellent
12.90%
Good
0.63%

Kobo Biotech Ltd Quarterly Performance

Latest quarterly metrics for KOBO — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

N/A

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

-8.13%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

N/A

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

12.21%

Compounded annual net profit growth over 5 years

Kobo Biotech Ltd Technical Indicators

SMA 50, SMA 200, RSI and volume signals for KOBO — calculated from daily price history

79RSI 14
Overbought — RSI 79

Momentum is strong — price may be stretched. Watch for pullbacks.

SMA 50
3
▲ Price above SMA 50 — Short-term bullish
SMA 200
3
▲ Price above SMA 200 — Long-term uptrend
30-Day Avg Volume
9K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

Kobo Biotech Ltd Financial Statements

Annual income statement, balance sheet and cash flow for Kobo Biotech Ltd (KOBO) — sourced from NSE/BSE filings.

Loading Financial Statements...

Fetching financial data for Kobo Biotech Ltd

About KOBO (Kobo Biotech Ltd)

Kobo Biotech Ltd is a dynamic force in the commodity chemicals sector, focusing on the innovative development and production of essential chemical building blocks. Positioned as a ...reliable partner for diverse industries, KOBO is committed to delivering high-quality chemical solutions that underpin various manufacturing processes. Through advanced research and development, KOBO ensures that its products meet the stringent standards required for a wide array of applications, from industrial manufacturing and agriculture to water treatment and specialized chemical formulations. KOBO is dedicated to providing cost-effective solutions and fostering strong, collaborative relationships with its clientele. Its commitment to sustainability and environmental stewardship is a core value, ensuring that its chemical products are produced in an eco-friendly manner. Leveraging cutting-edge technology and a team of skilled professionals, KOBO is capable of delivering customized chemical solutions tailored to the specific needs of its customers. Their state-of-the-art manufacturing facilities are designed for optimal efficiency and flexibility, enabling them to respond swiftly to changing market demands and maintain a competitive edge. KOBO continuously invests in research and development to identify new opportunities and create innovative chemical products that drive progress across industries. Their customer-centric approach involves close collaboration with clients, providing technical expertise and ensuring seamless integration of their chemical products into existing processes. KOBO's comprehensive portfolio of commodity chemicals caters to a broad spectrum of industries, providing essential components for a wide range of applications. From basic chemicals utilized in the production of plastics and textiles to specialty chemicals that enhance the performance of agricultural products and water treatment systems, KOBO delivers solutions that drive efficiency and innovation. With a strong focus on quality control and regulatory compliance, KOBO ensures that its products meet the highest standards of purity and safety. By prioritizing customer satisfaction and building long-term partnerships, KOBO aims to be a leading provider of commodity chemicals, contributing to the growth and success of its clients across diverse sectors.

Company Details

Symbol:KOBO
Industry:Commodity Chemicals
Sector:Commodity Chemicals

Key Leadership

Mr. Neelam Kumar Murdia
Chief Financial Officer
Mr. Rajendra Kumar P. Kaimal
Compliance Officer & Non-Executive Director

KOBO Share Price: Frequently Asked Questions

What is the current share price of Kobo Biotech Ltd?

Kobo Biotech Ltd (KOBO) trades at ₹4.33 on NSE and BSE. Market cap ₹6.39 (Cr). Educational data only.

What is the P/E ratio of Kobo Biotech Ltd?

Kobo Biotech Ltd has a P/E of N/Ax vs industry average 20.98x.

What is the Bull Run score for Kobo Biotech Ltd?

Kobo Biotech Ltd has a Bull Run score of 20.3/100 based on 25+ financial parameters.

Does Kobo Biotech Ltd pay dividends?

Kobo Biotech Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.

What is the ROE of Kobo Biotech Ltd?

Kobo Biotech Ltd has ROE of N/A. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of Kobo Biotech Ltd?

Kobo Biotech Ltd has debt-to-equity of N/A.

Is Kobo Biotech Ltd a good investment?

Bull Run gives Kobo Biotech Ltd a score of 20.3/100. This is not investment advice — consult a SEBI-registered advisor.